SGLT-2 Inhibitors: A New Mechanism for Glycemic Control.
about
The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapiesSGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectivesSpotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes: a systematic reviewSodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsPractical combination therapy based on pathophysiology of type 2 diabetesHuman genetics as a model for target validation: finding new therapies for diabetes.Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.Tofogliflozin: first global approval.Recommendations for management of diabetes during Ramadan: update 2015.Metabolic engineering of Saccharomyces cerevisiae for de novo production of dihydrochalcones with known antioxidant, antidiabetic, and sweet tasting properties.Adverse Effects Associated With Newer Diabetes Therapies.Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview.Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes.Role of Omentin, Vaspin, Cardiotrophin-1, TWEAK and NOV/CCN3 in Obesity and Diabetes DevelopmentSodium Glucose Transporter 2 Inhibitors and Diabetic Ketoacidosis in Three Patients with Diabetes: Underlying CausationCanagliflozin-associated Diabetic Ketoacidosis with Lower-than-anticipated Glucose Levels.Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice.
P2860
Q26744317-3F6C2152-1981-4FE7-9EA9-3658ECDBFE9EQ26746901-BCB13025-84D8-48CD-BA79-CD2F66EE05E3Q28071386-8A6376D5-D28A-490F-AFB1-97F3FDBC3058Q28072765-5578816B-8710-463A-AB2B-D362D0E94332Q28076530-8132BCD1-7BCA-44EF-B4E8-5DB79D7DCFD4Q30234640-8FDC0F45-BC5B-4D79-A07B-3F97DD168BA2Q33763305-655ABFB2-94AF-40F3-94DB-0D0B474862FFQ34420901-29CCDCD5-E63B-44B0-86A6-E681063AD812Q35768907-6E5CBAC0-A928-4BF7-B3CC-649142118442Q37596347-EB078D84-1127-4B87-B837-08BED9E3C5F6Q38546214-DD99CFE9-2651-4245-AB1A-0AEC2C71A61CQ38975736-46C225D1-3DD5-4FD4-A63A-7C4DFAB1C2A7Q39039079-F04EA274-3109-4DF2-9FF3-A70323E29C4CQ41574249-E8AF9734-DD87-4123-B06E-7212A9A4A5FCQ42699625-438F13F1-A7EA-4533-BC5E-CF413ADC16A2Q47105922-74BF791D-39FC-43B7-B6F4-2E622AAFFFCAQ51565743-EB13942A-987B-4D46-B9D6-A2CFC41B69EBQ53322628-BF192B86-DB24-4D0A-B9DF-79403EB1001C
P2860
SGLT-2 Inhibitors: A New Mechanism for Glycemic Control.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
SGLT-2 Inhibitors: A New Mechanism for Glycemic Control.
@ast
SGLT-2 Inhibitors: A New Mechanism for Glycemic Control.
@en
type
label
SGLT-2 Inhibitors: A New Mechanism for Glycemic Control.
@ast
SGLT-2 Inhibitors: A New Mechanism for Glycemic Control.
@en
prefLabel
SGLT-2 Inhibitors: A New Mechanism for Glycemic Control.
@ast
SGLT-2 Inhibitors: A New Mechanism for Glycemic Control.
@en
P2860
P356
P1433
P1476
SGLT-2 Inhibitors: A New Mechanism for Glycemic Control.
@en
P2093
Edward C Chao
P2860
P356
10.2337/DIACLIN.32.1.4
P577
2014-01-01T00:00:00Z